GSK3B and autoimmune thrombocytopenic purpura: This study aims to explore the effects of YC‐4‐3, the patented chemical synthesis of benzothiazepinone compounds (BTZs), a novel GSK‐3β inhibitor (GSK‐3βi), on macrophages in ITP.